業績公告
即時報告
8-K
2026-05-14
Forte Biosciences 提交8-K 披露首季業績 投資者關注研發進展及現金狀況
AI 繁中摘要
Forte Biosciences（納斯達克：FBRX）於2026年5月11日提交8-K即時報告，披露截至2026年3月31日止第一季度的財務業績。公司同日發佈新聞稿，惟新聞稿內容未隨8-K全文列出，具體營運數據及盈虧數字須參閱附件99.1。是次申報僅為「提供」性質（furnished），而非「存檔」（filed），不視為納入《交易所法》第18條責任範圍。投資者可留意新聞稿中可能提及的研發進展、現金狀況及未來指引。季度業績公佈通常引發股價波動，建議詳細閱讀原文以評估基本面變化。
展開英文正文
8-K false 0001419041 0001419041 2026-05-11 2026-05-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2026 FORTE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38052 26-1243872 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 3060 Pegasus Park Dr. Building 6 Dallas, Texas 75247 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: (310) 618-6994 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value FBRX The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02. Results of Operations and Financial Condition. On May 11, 2026, Forte Biosciences, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release dated May 11, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FORTE BIOSCIENCES, INC. Date: May 14, 2026 By: /s/ Antony Riley Antony Riley Chief Financial Officer